4516 Stock Overview
Nippon Shinyaku Co., Ltd. manufactures and sells pharmaceuticals and foodstuffs in Japan, Switzerland, and internationally.
Nippon Shinyaku Competitors
Price History & Performance
|Historical stock prices|
|Current Share Price||JP¥7,910.00|
|52 Week High||JP¥9,840.00|
|52 Week Low||JP¥7,000.00|
|1 Month Change||-4.81%|
|3 Month Change||-7.92%|
|1 Year Change||-3.65%|
|3 Year Change||-8.98%|
|5 Year Change||10.94%|
|Change since IPO||647.40%|
Recent News & Updates
|4516||JP Pharmaceuticals||JP Market|
Return vs Industry: 4516 underperformed the JP Pharmaceuticals industry which returned 6% over the past year.
Return vs Market: 4516 underperformed the JP Market which returned -0.1% over the past year.
|4516 Average Weekly Movement||6.6%|
|Pharmaceuticals Industry Average Movement||4.1%|
|Market Average Movement||3.9%|
|10% most volatile stocks in JP Market||8.1%|
|10% least volatile stocks in JP Market||2.1%|
Stable Share Price: 4516 is more volatile than 75% of JP stocks over the past 3 months, typically moving +/- 7% a week.
Volatility Over Time: 4516's weekly volatility (7%) has been stable over the past year, but is still higher than 75% of JP stocks.
About the Company
Nippon Shinyaku Co., Ltd. manufactures and sells pharmaceuticals and foodstuffs in Japan, Switzerland, and internationally. The company operates through Pharmaceuticals and Functional Food segments. It offers drugs for urological diseases, inflammation and allergies, hematologic malignancies, cardiovascular and metabolic diseases, gastrointestinal disorders, and other diseases.
Nippon Shinyaku Fundamentals Summary
|4516 fundamental statistics|
Is 4516 overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|4516 income statement (TTM)|
|Cost of Revenue||JP¥50.19b|
Last Reported Earnings
Mar 31, 2022
Next Earnings Date
Aug 09, 2022
|Earnings per share (EPS)||370.97|
|Net Profit Margin||18.17%|
How did 4516 perform over the long term?See historical performance and comparison
1.4%Current Dividend Yield
Does 4516 pay a reliable dividends?See 4516 dividend history and benchmarks
|Nippon Shinyaku dividend dates|
|Ex Dividend Date||Sep 29 2022|
|Dividend Pay Date||Dec 05 2022|
|Days until Ex dividend||52 days|
|Days until Dividend pay date||119 days|
Does 4516 pay a reliable dividends?See 4516 dividend history and benchmarks
Is 4516 undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score 3/6
Price-To-Earnings vs Peers
Price-To-Earnings vs Industry
Price-To-Earnings vs Fair Ratio
Below Fair Value
Significantly Below Fair Value
Key Valuation Metric
Which metric is best to use when looking at relative valuation for 4516?
Other financial metrics that can be useful for relative valuation.
|What is 4516's n/a Ratio?|
Price to Earnings Ratio vs Peers
How does 4516's PE Ratio compare to its peers?
|4516 PE Ratio vs Peers|
|Company||PE||Estimated Growth||Market Cap|
4506 Sumitomo Pharma
4536 Santen Pharmaceutical
4581 Taisho Pharmaceutical Holdings
4516 Nippon Shinyaku
Price-To-Earnings vs Peers: 4516 is expensive based on its Price-To-Earnings Ratio (21.3x) compared to the peer average (14.4x).
Price to Earnings Ratio vs Industry
How does 4516's PE Ratio compare vs other companies in the JP Pharmaceuticals Industry?
Price-To-Earnings vs Industry: 4516 is expensive based on its Price-To-Earnings Ratio (21.3x) compared to the JP Pharmaceuticals industry average (17.4x)
Price to Earnings Ratio vs Fair Ratio
What is 4516's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
|Current PE Ratio||21.3x|
|Fair PE Ratio||21.5x|
Price-To-Earnings vs Fair Ratio: 4516 is good value based on its Price-To-Earnings Ratio (21.3x) compared to the estimated Fair Price-To-Earnings Ratio (21.5x).
Share Price vs Fair Value
What is the Fair Price of 4516 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: 4516 (¥7910) is trading below our estimate of fair value (¥19091.98)
Significantly Below Fair Value: 4516 is trading below fair value by more than 20%.
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
Analyst Forecast: Target price is more than 20% higher than the current share price, but analysts are not within a statistically confident range of agreement.
Discover undervalued companies
How is Nippon Shinyaku forecast to perform in the next 1 to 3 years based on estimates from 2 analysts?
Future Growth Score1/6
Future Growth Score 1/6
Earnings vs Savings Rate
Earnings vs Market
High Growth Earnings
Revenue vs Market
High Growth Revenue
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: 4516's forecast earnings growth (6.3% per year) is above the savings rate (0.04%).
Earnings vs Market: 4516's earnings (6.3% per year) are forecast to grow slower than the JP market (8.6% per year).
High Growth Earnings: 4516's earnings are forecast to grow, but not significantly.
Revenue vs Market: 4516's revenue (4.1% per year) is forecast to grow slower than the JP market (4.4% per year).
High Growth Revenue: 4516's revenue (4.1% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: 4516's Return on Equity is forecast to be low in 3 years time (12.7%).
Discover growth companies
How has Nippon Shinyaku performed over the past 5 years?
Past Performance Score5/6
Past Performance Score 5/6
Growing Profit Margin
Earnings vs Industry
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: 4516 has high quality earnings.
Growing Profit Margin: 4516's current net profit margins (18.2%) are higher than last year (17%).
Past Earnings Growth Analysis
Earnings Trend: 4516's earnings have grown by 18.4% per year over the past 5 years.
Accelerating Growth: 4516's earnings growth over the past year (20.7%) exceeds its 5-year average (18.4% per year).
Earnings vs Industry: 4516 earnings growth over the past year (20.7%) exceeded the Pharmaceuticals industry 17.2%.
Return on Equity
High ROE: 4516's Return on Equity (13.8%) is considered low.
Discover strong past performing companies
How is Nippon Shinyaku's financial position?
Financial Health Score6/6
Financial Health Score 6/6
Short Term Liabilities
Long Term Liabilities
Financial Position Analysis
Short Term Liabilities: 4516's short term assets (¥149.7B) exceed its short term liabilities (¥32.0B).
Long Term Liabilities: 4516's short term assets (¥149.7B) exceed its long term liabilities (¥7.0B).
Debt to Equity History and Analysis
Debt Level: 4516 is debt free.
Reducing Debt: 4516 has not had any debt for past 5 years.
Debt Coverage: 4516 has no debt, therefore it does not need to be covered by operating cash flow.
Interest Coverage: 4516 has no debt, therefore coverage of interest payments is not a concern.
Discover healthy companies
What is Nippon Shinyaku current dividend yield, its reliability and sustainability?
Dividend Score 4/6
Cash Flow Coverage
Current Dividend Yield
Upcoming Dividend Payment
Dividend Yield vs Market
Notable Dividend: 4516's dividend (1.42%) isn’t notable compared to the bottom 25% of dividend payers in the JP market (1.63%).
High Dividend: 4516's dividend (1.42%) is low compared to the top 25% of dividend payers in the JP market (3.62%).
Stability and Growth of Payments
Stable Dividend: 4516's dividends per share have been stable in the past 10 years.
Growing Dividend: 4516's dividend payments have increased over the past 10 years.
Earnings Payout to Shareholders
Earnings Coverage: With its reasonably low payout ratio (29.7%), 4516's dividend payments are well covered by earnings.
Cash Payout to Shareholders
Cash Flow Coverage: With its reasonable cash payout ratio (61%), 4516's dividend payments are covered by cash flows.
Discover strong dividend paying companies
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Toru Nakai (51 yo)
Mr. Toru Nakai serves as the President of Nippon Shinyaku Co., Ltd. since June 2021 and served as its Head of Global Business Division since 2019 until June 2021 and serves as its Director at since June 20...
Experienced Management: 4516's management team is not considered experienced ( 1.4 years average tenure), which suggests a new team.
Experienced Board: 4516's board of directors are considered experienced (3.7 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
Nippon Shinyaku Co., Ltd.'s employee growth, exchange listings and data sources
- Name: Nippon Shinyaku Co., Ltd.
- Ticker: 4516
- Exchange: TSE
- Founded: 1911
- Industry: Pharmaceuticals
- Sector: Pharmaceuticals & Biotech
- Implied Market Cap: JP¥532.763b
- Shares outstanding: 67.35m
- Website: https://www.nippon-shinyaku.co.jp
Number of Employees
- Nippon Shinyaku Co., Ltd.
- 14, Nishinosho-Monguchi-cho
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2022/08/07 00:00|
|End of Day Share Price||2022/08/05 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.